{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:52:21Z","timestamp":1783734741228,"version":"3.55.0"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"5","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health-USA","doi-asserted-by":"crossref","award":["R01AR071653"],"award-info":[{"award-number":["R01AR071653"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000738","name":"United States Department of Veterans Affairs Merit Review","doi-asserted-by":"publisher","award":["BX005921-01"],"award-info":[{"award-number":["BX005921-01"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007496","name":"Biomedical Laboratory Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007496","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,28]]},"abstract":"<jats:p>Two measurement tools are currently used to assess skin disease activity in dermatomyositis (DM) clinical trials: the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) and the Cutaneous Dermatomyositis Investigator Global Assessment (CDM-IGA). This cross-sectional study assessed variability in erythema presentation across DM subtypes and among racial groups by comparing these two measurement tools: the CDASI and the CDM-IGA. With the increasing need to standardize DM trial outcome measures for cutaneous disease, our findings support the use of the CDASI as the primary scoring tool to determine cutaneous trial outcomes.<\/jats:p>","DOI":"10.1093\/bjd\/ljaf013","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T08:21:17Z","timestamp":1736324477000},"page":"943-945","source":"Crossref","is-referenced-by-count":2,"title":["Erythema variation in dermatomyositis across subtypes and racial groups: importance of outcome measure for dermatomyositis clinical trials"],"prefix":"10.1093","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-8838-1443","authenticated-orcid":false,"given":"Catherine","family":"Shen","sequence":"first","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA ,","place":["USA"]},{"name":"Corporal Michael J. Crescenz Veterans Affairs Medical Center , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ari","family":"Zeidi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA ,","place":["USA"]},{"name":"Corporal Michael J. Crescenz Veterans Affairs Medical Center , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lillian","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA ,","place":["USA"]},{"name":"Corporal Michael J. Crescenz Veterans Affairs Medical Center , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lais","family":"Lopes Almeida Gomes","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA ,","place":["USA"]},{"name":"Corporal Michael J. Crescenz Veterans Affairs Medical Center , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Feng","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria P","family":"Werth","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA ,","place":["USA"]},{"name":"Corporal Michael J. Crescenz Veterans Affairs Medical Center , Philadelphia, PA ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,1,8]]},"reference":[{"key":"2025042813572668100_ljaf013-B1","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/j.jid.2023.05.025","article-title":"Validation of Cutaneous Dermatomyositis Disease Area and Severity Index Activity Score and other efficacy outcomes as measures of skin disease in dermatomyositis in the Lenabasum phase 3 trial","volume":"143","author":"Pandya","year":"2023","journal-title":"J Invest Dermatol"},{"key":"2025042813572668100_ljaf013-B2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamadermatol.2024.5190","article-title":"Subtype and racial erythema \u00advariation for cutaneous lupus trials","volume":"161","author":"Xie","year":"2025","journal-title":"JAMA Dermatol"},{"key":"2025042813572668100_ljaf013-B3","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjd.13915","article-title":"Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change","volume":"173","author":"Anyanwu","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025042813572668100_ljaf013-B4","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/RHU.0000000000002031","article-title":"Racial disparities in diagnosis and treatment of patients with dermatomyositis of different skin tones","volume":"30","author":"Weisleder","year":"2024","journal-title":"J Clin Rheumatol"},{"key":"2025042813572668100_ljaf013-B5","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjd.15140","article-title":"The reliability of the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) among dermatologists, rheumatologists and neurologists","volume":"176","author":"Tiao","year":"2017","journal-title":"Br J Dermatol"},{"key":"2025042813572668100_ljaf013-B6","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.semarthrit.2020.01.002","article-title":"The validity and utility of the Cutaneous Disease Area and Severity Index (CDASI) as a clinical outcome instrument in dermatomyositis: a comprehensive review","volume":"50","author":"Ahmed","year":"2020","journal-title":"Semin Arthritis Rheum"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljaf013\/61372702\/ljaf013.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/5\/943\/61372702\/ljaf013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/5\/943\/61372702\/ljaf013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T17:57:33Z","timestamp":1745863053000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/5\/943\/7945316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,8]]},"references-count":6,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,1,8]]},"published-print":{"date-parts":[[2025,4,28]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljaf013","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,1,8]]}}}